Sterility assurance device developer Verrix said today that it raised $8 million in a Series B round of financing, lifting the total the company has raised so far to $17.5 million.
The San Clemente, Calif.-based company said that funding from the offering will support finalizing the development, regulatory submission and eventual commercialization of its Verrix EVA biological indicator system.
Verrix said that the system is intended to verify the success of sterilization cycles and to detect failures, and comes based off technology originally developed at NASA’s Jet Propulsion Laboratory.
The company added that it is aiming for a launch of the first BI system based on its technology some time next year.
“We are excited to see the rapid advancement of Verrix with strong support from our investors. The company has achieved significant progress in the development of the Verrix EVA BI System and is well positioned to successfully transition to commercialization as it prepares to introduce new technology for the fight against hospital acquired infections,” CEO Cameron Rouns said in a press release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.